Skip to content Skip to footer

INSIGHTS+

EMA Marketing Authorization of New Drugs in June 2025  
Shots:  The EMA’s CHMP has granted positive opinions and approvals to 2 Biologics and 6 new chemical entities in June 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drug was SpringWorks Therapeutics’ Ogsiveo to Treat Desmoid Tumours  PharmaShots has compiled a list of 8 drugs that have been…
Know Your Investor: Invus (July’25 Edition)
Shots:      Welcome to the 2025 edition of Know Your Investor, highlighting leading venture capital firms shaping the future of healthcare innovation  This edition highlights Invus, an investment firm focused on supporting life sciences companies committed to advancing breakthroughs that enhance public health  In 2024, Invus invested around $4.15B across six funding rounds, expanding its portfolio…
The US FDA New Drug Approvals in June 2025  
Shots:  PharmaShots has compiled a list of US FDA-approved drugs in the month of June 2025  The US FDA has approved a total of 5 new drugs, including 2 new molecular entities and 3 biologics, leading to the treatment of patients and advances in the pharmaceutical industry  The major highlighted drug was Daiichi Sankyo and AstraZeneca’s Datroway, securing…
Key Biosimilars Events of June 2025  
Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         Alvotech & Advanz Pharma Secure the CHMP’s Positive Opinion for AVT06. Our…
Q1 2025
PharmaShots’ Key Highlights of Second Quarter 2025 
Shots:    Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B    The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid    PharmaShots brings the Quarterly digest compiling insights from…
Disease of the Month – Angina 
Shots:  Characterized by discomfort or pain in the chest, Angina develops when the heart does not receive adequate oxygen-rich blood  PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types, symptoms, diagnosis, treatments, epidemiology, market size, clinical trial analysis, patient advocacy groups (PAGs),…
New Drug Designations – May 2025  
Shots:      PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA    The May 2025 report covers designations granted to 44 drugs and 5 medical devices, spanning 15 small molecules, 7 biologics, 13 cell and gene therapies & 5 medical devices among others   …
EMA Marketing Authorization of New Drugs in May 2025  
Shots:    The EMA’s CHMP has granted positive opinions and approvals to 4 Biologics and 2 New Chemical Entites in May 2025, leading to treatments for patients and advances in the healthcare industry   The major highlighted drugs were GSk’s Blenrep to Treat R/R Multiple Myeloma   PharmaShots has compiled a list of 4 drugs that have been…
FDA Drug Approvals May 2025
The US FDA New Drug Approvals in May 2025
Shots:      PharmaShots has compiled a list of US FDA-approved drugs in the month of May 2025       The US FDA has approved a total of 3 new drugs, including 2 new molecular entities and 1 Biologic leading to the treatment of patients and advances in the healthcare industry        The major highlighted drug was AbbVie’s Emrelis securing…
Know Your Investor: Deep Track Capital (June’25 Edition)
Shots:     Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation  This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health  In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…